CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Poised for First-Mover Advantage

Flora Growth Corp. (NASDAQ: FLGC) is aggressively pushing its brand and advancing the conversation around cannabis. “In addition, with its able management, Flora is recognizing and capitalizing on opportunities that others are yet to identify, placing it in a unique position that not only gives it a first-mover advantage but also presents a unique opportunity for growth,” a recent article that discusses a research report from Zacks reads. According to the report, 2021 saw Flora’s acquisition of Vessel Brand Inc., a move that allowed the company to establish a foothold in the United States cannabis accessories business while also improving its e-commerce capabilities. “The year would also see the construction of an all-outdoor cultivation and on-site extraction facility in Colombia, one of the largest traditional flower exporters in the world and now able to export cannabis flowers… Through its acquisitions and growing distribution network, Flora was able to post a 450% year-over-year revenue growth for the first quarter of the 2022 financial year. As a result, its management is confident that, for the entire fiscal year, the company will post between $35 million and $45 million in revenue… The company anticipates accelerating revenue growth in 2022 as it activates its Wholesale and Life Sciences growth units while simultaneously fueling expansion in the global House of Brands.”

To view the full article, visit https://cnw.fm/MSkLX

About Flora Growth Corp.

Flora is building a connected, design-led collective of plant-based wellness and lifestyle brands delivering the most compelling customer experiences in the world, one community at a time. As the operator of one of the most extensive outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its commercial, house of brands and life sciences divisions. Visit www.FloraGrowth.com or follow @floragrowthcorp on social media for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Partners to Propel New, Exciting Growth Opportunities

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently entered into agreements with beverage developer BevNology. “The BevNology collaboration not only includes a commercial license agreement for products with active ingredients derived from hemp under BevNology’s brand but also a manufacturing operating agreement utilizing BevNology’s new, custom-built state-of-the-art processing facility outside Atlanta…. The manufacturing agreement will help Lexaria broaden its production capabilities for its own growing list of B2B clientele interested in purchasing DehydraTECH-powered active ingredients for consumer-packaged-goods brands. Lexaria has already installed all required commercial DehydraTECH manufacturing equipment at the facility,” a recent article reads. “These agreements build on a long-standing and very successful product development consulting relationship between Lexaria and the expert scientists and personnel at BevNology,” Lexaria CEO Chris Bunka stated. “BevNology’s formulation and production capabilities are class leading and we are confident that our new relationship with our trusted partner will propel new and exciting growth opportunities for both companies.”

To view the full article, visit https://cnw.fm/WfeeJ

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Prime Harvest Inc. Subsidiary Receives Adult-Use Edibles Sales, Expansion Rights

Prime Harvest, a legal cannabis company focused on tech and parent company to Jaxx Cannabis, has been granted expansion rights of adult-use edibles sales through Jaxx. According to the announcement, Jaxx is Prime Harvest’s flagship retail brand and is driving strong growth for the company, reporting $4 million in sales last year alone. Through Jaxx, which only offers products that are licensed and regulated by California and San Diego County, consumers can order online 24/7 or purchase in a brick-and-mortar retail store and be assured that they are receiving the highest-quality products available. Jaxx offers a diverse array of products selected to create an experience focused and centered on consumers. The company everything from flower, pre-rolls, edibles and topicals to a complete line of accessories, including everything from bowls and spoons to entire starter kits and more. Prime Harvest is working to expand its footprint by investing in the growth and scale of licensed assets combined with fully utilizing the power of data-driven technology. Prime Harvest is focused on ensuring that the communities it serves see their fair share of the benefits of the industry’s growth, including employment opportunities, environmental enrichment and impactful innovation through R&D and education. “We are excited to expand and participate in the adult-use market, and even more than excited to expand our menu to include cannabis infused edibles for both our current medical patients as well as the recreational consumer,” said Prime Harvest founder and CEO Duane Alexander in the press release. “With the systems in place to drive our retail expansion, we are well on our way to execute on our strategically-designed plan for sustainable growth.”

To view the full press release, visit https://cnw.fm/8umfi

About Prime Harvest Inc.

Prime Harvest is a technology-focused, full-service cannabis corporation. The company is horizontally diversified across various segments of the cannabis value chain, including licensing acquisition and compliance management, and statewide direct-to-consumer operations. Based in the innovation hot spot of San Diego, California, Prime Harvest is expanding its footprint throughout the Golden State by executing a long-term strategy of investing in the growth and scale of licensed assets anchored by the power of data-driven technology. Prime Harvest’s flagship retail brand, Jaxx Cannabis, upholds exceptional standards of quality and services and provides a rewarding experience for customers in San Diego and the surrounding Southern California communities. Trust and credibility are at the heart of everything that the team at Prime Harvest stands for. The Prime Harvest team is composed of true experts in their respective fields, carefully assembled with the aim of building a world-class organization that can drive the cannabis industry and movement forward. For more information about the company, visit www.PrimeHarvestInc.com.

NOTE TO INVESTORS: The latest news and updates relating to Prime are available in the company’s newsroom at https://cnw.fm/PRIME

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (NASDAQ: LEXX) Offers Best-In Class Solution To Major Issue Affecting A Range Of Critical Drug Applications

Researchers have run into the issue of solubility of molecules intended for absorption, ultimately affecting drug effectiveness and inhibiting patient recovery
This has forced the exploration of new drug delivery technologies, with Lexaria’s patented DehydraTECH(TM) technology proving to be the most innovative, useful, and effective
DehydraTECH(TM) technology has seen application in oral nicotine for reduced risk, antiviral drugs for COVID-19 and other infectious diseases, PDE5 inhibitors, and CBD for hypertension
The recent expansion of the Cannadips Brand into Europe, Japan, and South Africa highlights the proliferation of DehydraTECH and a significant growth in its market share, particularly in the CBD space
Lexaria is excited about the expansion and anticipates additional growth in its technology’s adoption as time progresses

For a long time, the medical industry has sought ways to improve patient health by enhancing the delivery of therapeutic drugs to target sites. An especially critical problem researchers in this sector have encountered is the limited solubility of the molecules intended for absorption.

It is estimated that approximately 90% of preclinical drug candidates are low-solubility compounds. This presents a challenge regarding the compounds’ bioavailability and effectiveness of the drugs. The problem has led researchers to explore various drug delivery technologies, some of which have shown promise while others have failed (https://cnw.fm/1IiSL).

Lexaria Bioscience (NASDAQ: LEXX) has come forth with what they are confident is the best solution, their patented DehydraTECH(TM) technology. It has been regarded as one of the most innovative drug delivery technologies in years, proving useful in delivering a wide range of active pharmaceutical ingredients in a more palatable and effective way. In addition, studies repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, a benefit that opens significant possibilities for important drug delivery.

DehydraTECH application areas tested so far include CBD for hypertension, oral nicotine for reduced risk, antiviral drugs for COVID-19 and other infectious diseases and PDE5 inhibitors. A new sector showing promise is the CBD industry, valued at $4.1 billion in 2022 and projected to hit $111.8 billion by 2030 (https://cnw.fm/6pXty).

DehydraTECH’s application in the cannabis sector is seeing a boom, particularly with the recent expansion of Boldt Runners Corporation, a DehydraTECH licensee, into Europe, Japan, and South Africa (https://cnw.fm/S0Y49).

Boldt Runners Corporation owns the Cannadips Brand, whose Cannadips CBD dip pouch is the leading CBD pouch brand in the United States. As a tobacco-free, nicotine-free dip alternative, this product offers an effective way to get the benefits of CBD by leveraging Lexaria’s DehydraTECH delivery technology. The product is sold in over 6,500 stores across the United States, and its expansion beyond the country is a major step, not just for Boldt Runners but also for Lexaria.

As Lexaria’s list of licensees continues to grow, more consumers will benefit from the DehydraTECH technology. The company is confident that, as the adoption of this technology grows, it will not only help its partners offer clients superior performance and experiences, but also ramp up shareholder value.

“Lexaria’s technology is enabling increased market share and sales growth for our continually growing list of corporate clients,” noted Chris Bunka, Lexaria’s Chief Executive Officer (“CEO”).

“We are delighted to help these innovators of today and leaders of tomorrow offer their clients superior performance and experiences that competitors simply cannot match, and we are highly anticipatory of additional growth to come,” he added.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — VA Clarifies That Veterans Working in Cannabis Industry Can Apply for Home Loans

Although dozens of states have now legalized medical cannabis and studies have found that cannabis can be quite effective at treating issues such as and post-traumatic stress disorder, veterans often struggle to access cannabis. Furthermore, military veterans who work in state-legal cannabis industries often lack the benefits and protections from the U.S. Department of Veteran Affairs that veterans outside the industry enjoy because cannabis is still illegal at the federal level.

In a move that is sure to be met with praise from veterans, cannabis reform activists and industry stakeholders, the VA has clarified that veterans who work in the cannabis industry are eligible for home loans. However, the department noted that while vets who now draw their income from state-legal cannabis businesses can apply for home loans, some prospective lenders may not be willing to issue them loans. Such lenders see the instability caused by marijuana’s federal status as a Schedule I drug and they may not want to run the risk of veterans in the industry defaulting on their loans.

Even so, the VA stressed in a recent memo that since hemp is federally legal under the 2018 Farm Bill, veterans who work with hemp and hemp products should not be discriminated against when applying for home loans via the department’s benefits program. Ideally, this should cover veterans who work in the CBD industry as most of the cannabidiol on the market is derived from hemp, a nonpsychoactive type of cannabis.

The VA stressed that veterans who earn a living in the marijuana industry cannot be barred from obtaining a certificate of eligibility. This is a document that confirms a veteran’s eligibility for a Veteran Affair’s guaranteed loan.

The memo did note that the current federal ban on marijuana may make it difficult for lenders to establish if the income derived from cannabis businesses is stable and reliable enough to pay a home loan. As a result, the memo stated, such lenders may be uncomfortable relying on marijuana-derived income when they underwrite VA-guaranteed loans.

On the other hand, veterans who are involved in the retail sale of hemp fabric and cannabis-related products that are federally compliant would not run into the same issues when seeking home loans.

This is not the first time the VA has raised the issue of home-loan eligibility for veterans working in the cannabis industry. For example, in 2020, the department issued a report stating that drawing income from state-legal cannabis did not render a veteran ineligible for VA benefits.

As these inconsistencies are addressed one by one, more people will reap the benefits of being in jurisdictions where entities such as Flora Growth Corp. (NASDAQ: FLGC) are allowed to operate and make a difference in the community.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — California Wants Standardized THC Testing to Prevent Lab Shopping

America’s cannabis industry may be insanely lucrative, but it desperately lacks standardized regulations. Each state with a legal cannabis market has its own marijuana policies, leading to a patchwork of regulations across the country. And even within individual states, there tends to be little standardized regulation. In California, which is home to the largest cannabis market in the country, this manifests as THC “laboratory shopping.”

This term refers to cannabis companies that shop around for laboratories which are more likely to show that their products have higher THC concentrations to make them more popular. State cannabis regulators in California are now looking for public input on proposed rules that would finally create standardized marijuana testing techniques.

Regulators say that they are aware the insane demand for cannabis may cause some businesses to shop around for labs that use testing methodologies that are more likely to show higher concentrations of THC. Ideally, standardized testing methods would ensure different testing facilities use the same standard methodologies when running tests on cannabis products.

As such, the California Department of Cannabis Control (DCC) has announced that it is beginning the rulemaking process that would result in the development of standardized testing practices for every licensed laboratory in the state. Speaking in a press release, DCC director Nicole Elliot said that since individual labs leverage different testing methods, they may produce inaccurate data and inconsistent results on the cannabinoid content in cannabis products.

Elliot said that the department is working to provide standard testing procedures to ensure there is integrity in the cannabis market as well as accurate data on cannabinoid and terpene content for the consumers; these guidelines would undoubtedly boost confidence among industry stakeholders. As per the proposed Senate Bill 544, the DCC will be required to establish standardized methods for testing cannabinoids by the end of this year.

By requiring that cannabis testing laboratories only use testing standards provided by the DCC, Elliot says the department will protect public health by providing consumers with consistently accurate information about the contents of the cannabis products they consume. Aside from testing for cannabinoid and terpene levels, these tests are also crucial to ensuring that cannabis products on the shelves aren’t contaminated with pesticides, mold, heavy metals and residual solvents.

The DCC will accept public comments on the proposed cannabis testing regulations until Aug. 2, 2022. Furthermore, the department will hold a public hearing for individuals who would like to offer in-person testimonies on Aug. 1, 2022.

The efforts being made to close any regulatory loopholes that some sector actors have been exploiting will level the field for all licensed companies, including American Cannabis Partners, so that all play by the same rules with no one company enjoying an unfair market advantage.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Health Canada Remains Quiet on Timeline for Reviewing Marijuana Law

More than eight months after the Canadian government was supposed to begin a review of Canada’s 2018 adult-use legalization law, authorities have yet to begin the process. Additionally, Health Canada, the department in charge of the country’s national health policy, still hasn’t provided a timeline for reviewing the recreational cannabis law.

This delay has hindered the development of much-needed legislative reforms for the recreational cannabis industry, one industry executive believes. According to Aurora Cannabis senior vice president of global government relations Rick Savone, the legislative review needs to cover a lot before the industry can get the regulations it desperately needs.

However, he says that the government’s inaction means that precious little is getting done from a legislative or regulatory perspective. Savone also acts as the chairman of the Cannabis Council of Canada. The report, which was slated to start by October 2021, should have begun three years after Canada legalized adult-use marijuana.

The Cannabis Act that legalized recreational cannabis in Canada contained a provision requiring a review of the country’s legalization law three years after the law was enacted. When asked if the review had begun earlier this year, Health Canada spokeswoman Tammy Jarbeau declined to offer a specific timeline and stated that preparations for the review were underway.

More than four months later, the department still hasn’t provided a public timeline for the review process, leaving industry players waiting with bated breath. Savone says that most industry players are eagerly waiting to see how the statutory review goes before they can make the moves they need to make. In the meantime, however, he says that their competitors, especially those on the global scale, are steadily gaining market positions.

Stakeholders in Canada’s nascent recreational cannabis industry are anxious to cover issues such as government regulatory fees, potency limits for cannabis-infused edibles, excise taxes, and limitations on advertising and marketing once the review commences. Although the Cannabis Act doesn’t cover all of these issues, stakeholders say those issues still deserve to be addressed.

Fortunately, industry insiders will have a chance to discuss the issues in an upcoming cannabis roundtable that will bring together government officials as well as industry insiders to discuss key issues.

Although Health Canada hasn’t said why it hasn’t started the review, industry sources say there are several reasons behind this delay, including the coronavirus pandemic and the September 2021 snap election followed by the appointment of a new health minister.

The delays in Canada show that it isn’t only American-based companies such as Advanced Container Technologies Inc. (OTC: ACTX), which are being held back by the lack of progress in bringing national policies in line with the available science and the wishes of the people.

NOTE TO INVESTORS: The latest news and updates relating to Advanced Container Technologies Inc. (OTC: ACTX) are available in the company’s newsroom at https://cnw.fm/ACTX

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Connecticut Company Leverages DEA License to Supply Marijuana for Yale Research

CT Pharma, a Connecticut-based medical marijuana production and research company, made history in 2019 when the U.S. Drug Enforcement Administration allowed it to grow marijuana for FDA-approved research. It became the first state-licensed cannabis company that could legally provide cannabis for studies funded by the federal government, breaking the University of Mississippi’s monopoly on cultivating research-grade cannabis.

The university had been the only federally approved supplier of cannabis for years. Still, researchers regularly complained that the cannabis produced by the facility was low-grade and compromised the results of their studies.

In a move that is sure to be approved by the cannabis research community, CT Pharma is now partnering with Yale University to produce cannabis for research on whether cannabis-derived tablets can be effective treatments against pain and stress. Researchers from Yale University will use cannabis flower cultivated in CT Pharma’s Rocky Hill, Connecticut facility. The company’s president, Rino Ferrarese, said that this federally funded study will leverage plant material cultivated within a state-level medical program, making it unique compared to other cannabis studies.

Ferrarese is also the executive vice president of the north region for Verano Holdings, an Illinois-based company that recently acquired CT Pharma. In early 2020, he predicted that this study would end in the creation of an FDA-approved, cannabis-derived tablet that could be on the market as soon as 2025. He stated that the federal agency had finally “opened up” and no longer took decades to approve new therapies.

Ferrarese believes that the FDA is interested in approving more effective treatment therapies sooner but noted that both patients and the industry as a whole would benefit from being slow and meticulous.

Even so, obtaining FDA approval for the study was far from easy. According to Ferrarese, the FDA was particularly interested in seeing if CT Pharma’s cannabis was cultivated, extracted, manufactured and packaged under Good Manufacturing Practice Standards. The agency requested the cleaning logs, facility layout and cultivation batch records. Furthermore, CT Pharma was required to provide potency, microbiology and stability tests to prove that the cannabis biomass was not contaminated.

All in all, the agency asked CT Pharma for “reams and reams of information,” Ferrarese said, including analytical reports, master batch records, facility control documentation and training records for all facility staff.

Yale University of Medicine professor Ranjita Sinha is in charge of the study and has already made some headway in the pain-management study. Her team discovered that a 40 mg CBD tablet with a low-THC dose and a 100 mg CBD tablet with little THC are reasonably efficient at alleviating pain.

As more research entities gain access to research-grade cannabis, which is representative of the marijuana products that consumers buy from state-legal sources, the public is bound to obtain a deeper understanding of how the products of regulated companies such as Prime Harvest Inc. can impact their health for the better and any drawbacks to such cannabis use.

NOTE TO INVESTORS: The latest news and updates relating to Prime Harvest Inc. are available in the company’s newsroom at https://cnw.fm/PRIME

About CNW420

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Sugarmade Inc. (SGMD) Benefiting from ‘Snowballing’ Fresh Frozen Cannabis Market

Sugarmade (OTC: SGMD), an emerging leader in the licensed cannabis sector, recently announced the first transaction under its contract with Cannabis Global Inc. (OTC: CBGL). “The transaction calls for Sugarmade to produce an estimated 25,000 pounds of Fresh Frozen cannabis, which Cannabis Global will use in its product lines and will distribute to the California marketplace. Sugarmade and Cannabis Global have signed a prebooked, fixed-price contract in the amount of $700,000…” a recent article reads. This comes as a growing number of cannabis consumers are choosing Fresh Frozen cannabis, which is flash frozen immediately after harvest instead of undergoing the traditional treatment of drying and curing, as they seek naturally produced cannabis products full of plant terpenes and flavors. Cannabis Global CEO Arman Tabatabaei is quoted saying, “The market for Fresh Frozen cannabis is snowballing. Thus, we believe it is the place to be for the 2022 cultivation season. We plan to process a large portion of the 25,000 pounds of ultra-premium cannabis at our Lynwood, California, laboratory, creating premium solventless extracts for sale into the market and for use in our own manufactured products, thus creating vertical integration to reduce our costs of goods sold.”

To view the full article, visit https://cnw.fm/OBbxH

About Sugarmade Inc.

Sugarmade is a product and branding marketing company investing in operations and technologies with disruptive potential. The company’s portfolio includes CarryOutsupplies.com, SugarRush, NUG Avenue, Lemon Glow and Budcars. For more information, please visit www.Sugarmade.com.

NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://cnw.fm/SGMD

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Awarded Patent in Japan, Submits Briefing Book

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, announced that it has been notified that it will be awarded a new patent in Japan, which makes the 26th world patent for the company. The patent, which is the third one granted in Japan, recognizes the company’s patented drug-delivery technology, DehydraTECH(TM), and its ability to deliver active pharmaceutical ingredients (“APIs”) more efficiently, regardless of the “food effect,” or the presence of food in the gastrointestinal system. Drug delivery is a key component of reliable drug dosing. According to the announcement, this is the first patent issued from Lexaria’s seventh patent family and is related to tetrahydrocannabinol (“THC”). The company also noted that it has patents granted or patent applications progressing in countries around the world. Lexaria also reported that the company had submitted its briefing book to the US Food and Drug Administration (“FDA”), which was required for the upcoming pre-Investigational New Drug (“IND”) meeting that the company has requested.

To view the full press release, visit https://cnw.fm/iux4X

About Lexaria Bioscience Corp.

Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 25 patents granted, plus a 26^th patent allowed, as well as an estimated 50 patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

To receive SMS text alerts from CannabisNewsWire, text “Cannabis” to 844-397-5787 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.